Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China

被引：0
|
作者：
Lei Liu
Zhen Ruan
Carolina Oi Lam Ung
Yawen Zhang
Yang Shen
Sheng Han
Ruxu Jia
Jingtao Qiao
Hao Hu
Lixin Guo
机构：
[1] Chinese Academy of Medical Sciences,Department of Pharmacy, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine
[2] University of Macau,State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences
[3] University of Macau,Department of Public Health and Medicinal Administration, Faculty of Health Sciences
[4] Novo Nordisk (China) Pharmaceuticals Co.,School of Public Health
[5] Ltd.,International Research Center for Medicinal Administration
[6] Peking University,Global Business School for Health
[7] Peking University,Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine
[8] University College London,undefined
[9] Chinese Academy of Medical Sciences,undefined
来源：
Diabetes Therapy | 2023年 / 14卷
关键词：
Cost-effectiveness analysis; Type 2 diabetes; Glucagon-like peptide-1 analogue; Semaglutide; PEG-loxenatide; China;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：93 / 107
页数：14
相关论文
共 50 条
  • [1] Long-Term Cost-Effectiveness of Subcutaneous Once-Weekly Semaglutide Versus Polyethylene Glycol Loxenatide for Treatment of Type 2 Diabetes Mellitus in China
    Liu, Lei
    Ruan, Zhen
    Ung, Carolina Oi Lam
    Zhang, Yawen
    Shen, Yang
    Han, Sheng
    Jia, Ruxu
    Qiao, Jingtao
    Hu, Hao
    Guo, Lixin
    [J]. DIABETES THERAPY, 2023, 14 (01) : 93 - 107
  • [2] COST-EFFECTIVENESS ANALYSIS OF ONCE-WEEKLY SEMAGLUTIDE VERSUS POLYETHYLENE GLYCOL LOXENATIDE FOR TREATMENT OF TYPE 2 DIABETES IN CHINA
    Liu, L.
    Zhen, R.
    Ung, C. O. L.
    Shen, Y.
    Zhang, Y.
    Han, S.
    Jia, R.
    Qiao, J.
    Hu, H.
    Guo, L.
    [J]. VALUE IN HEALTH, 2022, 25 (12) : S116 - S116
  • [3] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Shuyan Gu
    Jinghong Gu
    Xiaoyong Wang
    Xiaoling Wang
    Lu Li
    Hai Gu
    Biao Xu
    [J]. Health Economics Review, 14
  • [4] The long-term cost-effectiveness of once-weekly semaglutide versus sitagliptin for the treatment of type 2 diabetes in China
    Gu, Shuyan
    Gu, Jinghong
    Wang, Xiaoyong
    Wang, Xiaoling
    Li, Lu
    Gu, Hai
    Xu, Biao
    [J]. HEALTH ECONOMICS REVIEW, 2024, 14 (01)
  • [5] Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK
    Viljoen, Adie
    Hoxer, Christina S.
    Johansen, Pierre
    Malkin, Samuel
    Hunt, Barnaby
    Bain, Stephen C.
    [J]. DIABETES OBESITY & METABOLISM, 2019, 21 (03): : 611 - 621
  • [6] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
    Malkin, Samuel J. P.
    Russel-Szymczyk, Monika
    Liidemann, Girtel
    Volke, Vallo
    Hunt, Barnaby
    [J]. DIABETES THERAPY, 2019, 10 (01) : 159 - 176
  • [7] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
    Johansen, Pierre
    Chubb, Barrie
    Hunt, Barnaby
    Malkin, Samuel J. P.
    Sandberg, Anna
    Capehorn, Matthew
    [J]. ADVANCES IN THERAPY, 2020, 37 (05) : 2427 - 2441
  • [8] The Management of Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide: A Long-Term Cost-Effectiveness Analysis in Slovakia
    Malkin, Samuel J. P.
    Russel-Szymczyk, Monika
    Psota, Marek
    Hlavinkova, Lucia
    Hunt, Barnaby
    [J]. ADVANCES IN THERAPY, 2019, 36 (08) : 2034 - 2051
  • [9] Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes: A Long-Term Cost-Effectiveness Analysis in Estonia
    Samuel J. P. Malkin
    Monika Russel-Szymczyk
    Girtel Liidemann
    Vallo Volke
    Barnaby Hunt
    [J]. Diabetes Therapy, 2019, 10 : 159 - 176
  • [10] Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK
    Pierre Johansen
    Barrie Chubb
    Barnaby Hunt
    Samuel J. P. Malkin
    Anna Sandberg
    Matthew Capehorn
    [J]. Advances in Therapy, 2020, 37 : 2427 - 2441
12345